Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsTrends

COVID-19 | Cadilla, Dr Reddy's and 5 other pharma firms cut Remdesivir injection prices on govt intervention

Prices of Remdesivir, an injection used in the treatment of COVID-19, have been voluntarily curtailed by various drug companies on the intervention of the government, National Pharmaceutical Pricing Authority (NPPA) said.

April 17, 2021 / 08:02 PM IST
Remdesivir | Representative Image

Remdesivir | Representative Image


Prices of Remdesivir injection have been voluntarily curtailed by various drug companies on the intervention of the government, National Pharmaceutical Pricing Authority (NPPA) said on Saturday.

Drug companies like Cadila Healthcare, Dr Reddy's Laboratories and Cipla have cut the prices of their respective brands of Remdesivir injection (100 mg/vial). The antiviral drug is used in the treatment of COVID-19. "Due to the government's intervention, the price of #Remdesivir Injection is now reduced! I am thankful to pharmaceutical companies for joining hands with the Government to fight against COVID-19 Pandemic," Union Minister of State for Chemicals and Fertilisers Mansukh L Mandaviya tweeted.

Union Minister Sadananda Gowda also hailed the decision taken by the drug companies. In a tweet, he said: "In a huge relief to people in this crucial time, after govt's intervention, the price of #Remdesivir is now reduced! I am grateful to pharma companies for standing along with PM @narendramodi's fight against #Covid." In a tweet, he said.

According to the details shared by the NPPA, Cadila Healthcare has reduced the price of its REMDAC (Remdesivir 100 mg) injection to Rs 899 from Rs 2,800 earlier. Similarly, Syngene International has cut the price of its brand RemWin to Rs 2,450 from Rs 3,950 earlier. Hyderabad-based Dr Reddy's Laboratories has cut the price of REDYX, which used to cost Rs 5,400 earlier to Rs 2,700 now. Similarly, Cipla has reducedP of its CIPREMI brand to Rs 3,000 from Rs 4,000 earlier. Hyderabad-based Dr Reddy's Laboratories has cut the price of REDYX, which used to cost Rs 5,400 earlier to Rs 2,700 now.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

Mylan has also reduced the price of its brand from Rs 4,800 to Rs 3,400. Similarly, Jubilant Generics has cut the price of its remdesivir brand to Rs 3,400 from Rs 4,700 earlier. Hetero Healthcare has also cut the price of its brand COVIFOR from Rs 5,400 to Rs 3,490 now.

On April 17, A war of words broke out between Union Minister Mansukh L Mandaviya and NCP leader Nawab Malik on the availability of antiviral drug Remdesivir, which is used in the treatment of COVID-19. Malik, in a series of tweets, alleged that the central government is not giving permission to various export-oriented units (EoUs) in the country to sell the drug in the domestic market.

These words were strongly refuted by Minister of State of Chemicals and Fertilisers Mandaviya who said the government is making every effort to double the production of the drug in the country. "Tweets by @nawabmalikncp are shocking. It is full of half-truths and lies and the threats issued are unacceptable. He is unaware of the ground situation. GoI has been in active contact with officers of GoM and is assisting with the supply of Remdesivir in every manner," he tweeted.

In another tweet, he said:"As per the Government's record, there is only one unit of EoU and one in SEZ. We have reached out to all the Manufacturers of Remdesivir. No such consignment is stuck. I request you (Malik) to share the list of these 16 companies, availability of stock and WHO-GMP with them." The central government is committed to doing everything to help the people, Mandaviya added.

Earlier Malik, a minister in the Maharashtra government, alleged that there were 16 EoUs in the country that has 20 lakh vials of Remdesivir available with them. "Since exports are now banned by the government, these units are seeking permission to sell this medicine in our country but the central government is denying the same," he tweeted.


first published: Apr 17, 2021 06:29 pm

stay updated

Get Daily News on your Browser